NCT01808937 Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
| NCT ID | NCT01808937 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Texas Southwestern Medical Center |
| Condition | Scleroderma, Localized |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2007-05 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2007-05 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Morphea in Adults and Children (MAC) cohort is the first registry for both children and adults with morphea (also known as localized scleroderma) in the country. The purpose of the registry is to learn more about morphea, specifically: * How morphea behaves over time * How frequently specific problems occur along with morphea (for example, arthritis) * Whether morphea has an autoimmune background
Eligibility Criteria
Inclusion Criteria: 1. Patient must have a clinical diagnosis of morphea confirmed by the primary investigator and by histopathological examination. 2. Ages 0-90 years old 3. Children must weigh more than 20 lbs. in order to satisfy Children's Medical Center policy for the maximum amount of blood drawn in a 24 hour period. 4. Patient or legal guardian must be able to speak and read at a 6th grade reading level. 5. Both male and female patients will be eligible 6. All races and ethnic backgrounds will be included 7. Relationships to proband: All patients with morphea will be included. A patient's family history will be reviewed and if there is a family history of morphea or systemic sclerosis then we will give the study patient the investigator's contact information and ask the family member to call the study team to answer any questions and enroll them in the study if they choose to do so. 8. Ability to give informed consent: Patients must be able to give informed consent or they will give assent with parent or guardian consent as a minor to be a part of the morphea registry. Exclusion Criteria: \- Patients who have been coded as morphea (701.0), but do not have morphea/localized scleroderma (examples: steroid atrophy, acquired keratoderma, keloids, nephrogenic fibrosing dermopathy, systemic sclerosis, lichen sclerosis)
Contact & Investigator
Heidi Jacobe, MD, MSCS
PRINCIPAL INVESTIGATOR
University of Texas Southwestern Medical Center
Frequently Asked Questions
Who can join the NCT01808937 clinical trial?
This trial is open to participants of all sexes, up to 90 Years, studying Scleroderma, Localized. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01808937 currently recruiting?
Yes, NCT01808937 is actively recruiting participants. Contact the research team at heidi.jacobe@utsouthwestern.edu for enrollment information.
Where is the NCT01808937 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT01808937 clinical trial?
NCT01808937 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is Heidi Jacobe, MD, MSCS at University of Texas Southwestern Medical Center. The trial plans to enroll 500 participants.